AstraZeneca PLC
23 October 2006
FDA Approves AstraZeneca's SEROQUEL(R) for Bipolar Depression Treatment
AstraZeneca has announced that the U.S. Food and Drug Administration (FDA) has
approved SEROQUEL(R) (quetiapine fumarate) for the treatment of patients with
depressive episodes associated with bipolar disorder. SEROQUEL already is
approved for the treatment of acute manic episodes associated with bipolar I
disorder and for the treatment of schizophrenia. SEROQUEL is now the first and
only single medication approved by the FDA to treat both depressive and manic
episodes associated with bipolar disorder.
The FDA approval was based primarily on results from the clinical trial
programme known as BOLDER (BipOLar DEpRession), which comprises the BOLDER I and
BOLDER II studies. In these studies, patients taking SEROQUEL showed an
improvement in depressive symptoms starting at week one compared to those taking
placebo, and this improvement continued throughout the eight-week study. The
recommended dose is 300 mg once-daily, to be achieved by day four of treatment.
More than seven million American adults are affected by bipolar disorder, a
serious psychiatric condition also known as manic depressive illness. Patients
with bipolar disorder are symptomatic almost half of their lives, and
approximately two-thirds of that time is spent in the depressed phase of the
illness. For many people with bipolar disorder, the depressive symptoms are
significantly more debilitating than the manic symptoms associated with the
illness.
'The new indication for SEROQUEL provides physicians and their patients with a
single medication to treat both the depressive and manic episodes associated
with bipolar disorder,' said John Patterson, Executive Director Development,
AstraZeneca. 'Treating acute bipolar disorder with a single medication may help
patients adhere to their medication regimen.'
Both studies in the BOLDER programme were double-blind, placebo-controlled
trials of outpatients (N=1,045) with bipolar I or II disorder. Patients were
randomized to receive eight weeks of treatment with fixed doses of SEROQUEL(R)
(300 mg or 600 mg) or placebo administered once-daily. Efficacy in bipolar
depression was demonstrated in the studies at both 300 mg a day and 600 mg a
day. No additional benefit was seen in the 600 mg a day dose groups.
Therefore, the recommended dose is 300 mg once-daily, to be achieved by day four
of treatment.
SEROQUEL was generally well tolerated, with adverse event types similar to those
seen in other clinical trials of SEROQUEL in bipolar mania and schizophrenia.
The most frequent adverse events seen in the bipolar depression trials were dry
mouth, sedation, somnolence, dizziness and constipation.
Because the depressive symptoms associated with bipolar disorder are also seen
in major depressive disorder, a proper diagnosis can be difficult to achieve. In
fact, studies show that as many as 69 percent of people with bipolar disorder
were misdiagnosed, with the most frequent misdiagnosis being major depressive
disorder. This misdiagnosis can lead to unfocused treatment that may exacerbate
the disease.
Beyond schizophrenia, bipolar mania and bipolar depression, the ongoing clinical
development programme includes investigations of the use of SEROQUEL in bipolar
maintenance. Regulatory filings for the treatment of schizophrenia with a
sustained release formulation of quetiapine fumarate, SEROQUEL SR(TM), were
submitted this year to regulatory authorities in the US, EU and other markets.
Ongoing SEROQUEL SR(TM) clinical studies also cover major depressive disorder
and generalized anxiety disorder. SEROQUEL is the number 1 prescribed atypical
antipsychotic in the United States. With a well-established safety and efficacy
profile, SEROQUEL has had more than 19 million patient exposures worldwide since
its launch in 1997. In 2005, global sales for SEROQUEL reached $2.8 billion.
23 October 2006
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Ed Seage, Tel: +1 302 886 4065
Jorgen Winroth, Tel +1 (212) 579 0506
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.